Joop ter Horst leads an application driven fundamental research group that will facilitate the paradigm shift to continuous manufacturing in the pharmaceutical industry. The group will identify routes to exploit the fundamental principles relating molecule, crystal structure and crystallization process phenomena to the crystal product quality to come to hybrid separation technologies to be incorporated in the continuous pharmaceutical manufacturing chain. He adopts a view from the molecular level and up for gaining fundamental understanding to use in control and prediction of new industrial crystallization processes. He cooperates with many university groups inside and outside the UK and his research benefits many industrial partners.
- Tutorial Industrial Crystallization Fundamentals
- Crystal Nucleation in Complex Multicomponent Solutions
- biwic 2017
- External Examiner for the PhD student Sharlinda Salim Sachithananthan in the Group of Prof. Sven Schroeder, Leeds University
- Lina Harfouche
- Giuseppe Belletti
more professional activities
- to develop a workflow for the rapid measurement of phase diagrams for multicomponent systems student placement Olayinka Olalere
- Ter Horst, Joop (Principal Investigator)
- 01-Jan-2018 - 31-Jan-2019
- Doctoral Training Partnership (DTP 2016-2017 University of Strathclyde) | Walsh, Erin
- Markl, Daniel (Principal Investigator) Ter Horst, Joop (Co-investigator) Walsh, Erin (Research Co-investigator)
- 01-Jan-2018 - 01-Jan-2021
- CMAC Core project: Impurity Rejection
- Florence, Alastair (Principal Investigator) Ter Horst, Joop (Co-investigator)
- 01-Jan-2017 - 30-Jan-2019
- Future Continuous Manufacturing and Advanced Crystallisation Research Hub (CMAC Hub)
- Florence, Alastair (Principal Investigator) Halbert, Gavin (Co-investigator) Johnston, Blair (Co-investigator) Nordon, Alison (Co-investigator) Price, Chris John (Co-investigator) Sefcik, Jan (Co-investigator) Ter Horst, Joop (Co-investigator)
- "Our Hub research is driven by the societal need to produce medicines and materials for modern living through novel manufacturing processes. The enormous value of the industries manufacturing these high value products is estimated to generate £50 billion p.a. in the UK economy. To ensure international competitiveness for this huge UK industry we must urgently create new approaches for the rapid design of these systems, controlling how molecules self-assemble into small crystals, in order to best formulate and deliver these for patient and customer. We must also develop the engineering tools, process operations and control methods to manufacture these products in a resource-efficient way, while delivering the highest quality materials.
Changing the way in which these materials are made, from what is called batch crystallisation (using large volume tanks) to continuous crystallisation (a more dynamic, flowing process), gives many advantages, including smaller facilities, more efficient use of expensive ingredients such as solvents, reducing energy requirements, capital investment, working capital, minimising risk and variation and, crucially, improving control over the quality and performance of the particles making them more suitable for formulation into final products. The vision is to quickly and reliably design a process to manufacture a given material into the ideal particle using an efficient continuous process, and ensure its effective delivery to the consumer. This will bring precision medicines and other highly customisable projects to market more quickly. An exemplar is the hubs exciting innovation partnership with Cancer Research UK.
Our research will develop robust design procedures for rapid development of new particulate products and innovative processes, integrate crystallisation and formulation to eliminate processing steps and develop reconfiguration strategies for flexible production. This will accelerate innovation towards redistributed anufacturing, more personalisation of products, and manufacturing closer to the patient/customer. We will develop a modular MicroFactory for integrated particle engineering, coupled with a fully integrated, computer-modelling approach to guide the design of processes and materials at molecule, particle and formulation levels. This will help optimise what we call the patient-centric supply chain and provide customisable products. We will make greater use of targeted experimental design, prediction and advanced computer simulation of new formulated materials, to control and optimise the processes to manufacture them.
Our talented team of scientists will use the outstanding capabilities in the award winning £34m CMAC National Facility at Strathclyde and across our 6 leading university spokes (Bath, Cambridge, Imperial, Leeds, Loughborough, Sheffield). This builds on existing foundations independently recognised by global industry as 'exemplary collaboration between industry, academia and government which represents the future of pharmaceutical manufacturing and supply chain framework'.
Our vision will be translated from research into industry through partnership and co-investment of £31m. This includes 10 of world's largest pharmaceutical companies (eg AstraZeneca, GSK), chemicals and food companies (Syngenta, Croda, Mars) and 19 key technology companies (Siemens, 15 SMEs) Together, with innovation spokes eg Catapult (CPI) we aim to provide the UK with the most advanced, integrated capabilities to deliver continuous manufacture, leading to better materials, better value, more sustainable and flexible processes and better health and well-being for the people of the UK and worldwide. CMAC will create future competitive advantage for the UK in medicines manufacturing and chemicals sector and is strongly supported by industry / government bodies, positioning the UK as the investment location choice for future investments in research and manufacturing."
- 01-Jan-2017 - 31-Jan-2023
- Scale-Up and Continuos Viedma Ripening
- Steendam, Rienk (Co-investigator) ter Keurst, Marc (Research Co-investigator) Ter Horst, Joop (Principal Investigator)
- Viedma ripening involves the transformation of a racemic mixture of chiral crystals into one chiral form. Attempts were made to scale-up this process but failed. In this project the reason for the failed scale-up attempts will be investigated. Scale-up and continuous Viedma ripening will be attempted in a different manner using different setups, compounds and different crystal size distributions.
- 07-Jan-2016 - 12-Jan-2017
- Doctoral Training Partnership (DTP 2016-2017 University of Strathclyde) | Moreno Leon, Carlos
- Ter Horst, Joop (Principal Investigator) Roy, Sudipta (Co-investigator) Moreno Leon, Carlos (Research Co-investigator)
- 01-Jan-2016 - 01-Jan-2020
Strathclyde Institute of Pharmacy and Biomedical Sciences
Technology Innovation Centre
View University of Strathclyde in a larger map